![1]()
News
USPSTF: Don’t add ECG for cardio risk assessment
June 12, 2018
Evidence is insufficient to assess risks vs. benefits of screening ECG for asymptomatic adults.
![1]()
News
DOAC’s edge over warfarin fades with low adherence
June 12, 2018
BOSTON – When atrial fib patients adhere to a direct oral anticoagulant it outperforms warfarin, but when compliance falls the tables get turned.
![1]()
Opinion
Kawasaki disease: New info to enhance our index of suspicion
May 30, 2018
Now the seasonality trends appear blurred in the youngest cases and the male predominance is blurred in the oldest cases.
![1]()
News
Safety of MRI in patients with implantable cardiac devices
May 29, 2018
Is MRI safe for patients who have implanted ICD or pacemakers that have not been deemed to be “MRI conditional” by the Food and Drug Administration?
![1]()
News
LAAC in nonvalvular AF provides stroke protection comparable to warfarin
May 24, 2018
Is mechanical left atrial appendage closure (LAAC) as effective as warfarin at preventing stroke in patients with nonvalvular atrial fibrillation?
![1]()
News
Guidelines to optimize treatment of reduced ejection fraction heart failure
May 18, 2018
What guidance is there for clinical care of complex heart failure patients?
![1]()
News
Long-acting bronchodilators increase CVD risk in certain COPD patients
May 17, 2018
Is the initiation of inhaled long-acting beta2-agonist (LABA) or long-acting muscarinic antagonists (LAMA) in patients with chronic obstructive pulmonary disease (COPD) associated with increased cardiovascular disease (CVD) risk?
![1]()
News
Design limitations may have compromised DVT intervention trial
May 14, 2018
WASHINGTON – The preferred evaluation – intravascular ultrasound – was not used.
![1]()
News
Thirty-second atrial fib threshold may drive overdiagnosis
May 10, 2018
BOSTON – The current 30-second threshold for defining clinically meaningful AF “metastasized” from a select subgroup of patients to all AF settings.
![1]()
News
First reversal agent for apixaban and rivaroxaban gets fast-track approval
May 4, 2018
Andexanet alfa approval puts factor Xa inhibitors in the same ballpark as dabigatran, reversible with idarucizumab.
